The LEAD series, which commenced in 2006 and involved 1041 adults from 21 countries, investigated the efficacy and safety of liraglutide, a human GLP-1 analog, in the treatment of type 2 diabetes mellitus (T2DM). This evidence concerns the gene GLP1R and diabetes mellitus.